Side-by-side comparison of AI visibility scores, market position, and capabilities
SF YC W21 alcohol reduction app at $13M ARR with 150K+ paying customers; $17.4M Series B Goodwater 2022 with neuroscience-based CBT and community support competing with Monument for gray-area drinker digital behavior change.
Reframe (formerly Glucobit) is a San Francisco-based digital health platform — backed by Y Combinator (W21) — providing people seeking to quit or reduce alcohol consumption with a neuroscience-based mobile app that combines behavioral psychology, habit tracking, and community support, achieving $13 million in annual revenue with 150,000+ paying customers after 10x growth in 12 months and 3,000% growth in 6 months to become one of the top health apps on the App Store. Founded in 2018 by Ziyi Gao and Vedant Pradeep, Reframe raised $17.4 million in a Series B in January 2022 from Goodwater Capital, applying evidence-based alcohol reduction techniques (including CBT, mindfulness, and neuroscience education about alcohol's brain effects) to the 30 million Americans who want to drink less but don't seek traditional addiction treatment.
Mass spectrometry sample prep and data science platform delivering 100x productivity for biopharma protein analysis; $9.1M from Merck Digital Sciences Studio, NIH, and YC at $1.8M revenue.
Andson Biotech is an Atlanta-based healthcare technology company providing mass spectrometry solutions for biopharma and biomanufacturing — offering the DynaCHIP hardware system (a novel mass spectrometry sample preparation platform) and DynaMARK data science module that together deliver up to 100x productivity improvements in protein and biomolecule analysis workflows compared to conventional mass spectrometry setups. Backed by Y Combinator, Merck Digital Sciences Studio, and NIH with $9.1 million raised, Andson achieved $1.8 million in revenue as of December 2024.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.